Zura Bio Ltd. is a clinical-stage biotechnology company that engages in the development of novel medicines for immune disorders. The company is headquartered in La Jolla, California and currently employs 14 full-time employees. The company went IPO on 2021-07-16. The company is developing three assets which have completed Phase I/Ib studies and are Phase II ready. The company is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), ZB-168, and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other novel indications with unmet needs. Tibulizumab (ZB-106) is an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of TALTZ (ixekizumab) and tabalumab that neutralizes IL-17A and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain (IL-7R) alpha. Torudokimab (ZB-880) is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.

ZURA Profile, Market Tickers and Other

ZURA profile